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A Cause of Aspirin Resistance?*
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Millions of people take aspirin every day for the prevention
of atherothrombotic cardiovascular events. Aspirin inhibits
thrombus formation by irreversibly inactivating the cyclo-
oxygenase (COX)-1 enzyme in platelets, thereby blocking
platelet production of thromboxane A2, a potent vasocon-
strictor and platelet agonist (1). Multiple studies have
reported that in some individuals the effectiveness of aspirin
for cardiovascular prevention is limited by “resistance” to its
antiplatelet effects (2). Although the validity of aspirin
resistance, as an entity, continues to be debated, observa-
tional studies consistently show that as many as one-third of
individuals prescribed aspirin have less-than-expected inhi-
bition of platelet function, which is independently associ-
ated with an increased risk of cardiovascular events (3–5).
See page 752
So-called aspirin resistance can often be overcome simply by
improving patient adherence or increasing the dose or
frequency of aspirin treatment (6–9), but there are also
unequivocal causes of aspirin resistance, such as drug–drug
interactions in which nonsteroidal anti-inflammatory drugs
prevent access of aspirin to platelet COX-1 (2).
Suboptimal platelet inhibition by aspirin (aspirin resis-
tance) is particularly common in patients undergoing coro-
nary artery bypass graft (CABG) surgery and, in this setting,
is often attributed to an increased rate of platelet production
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Both authors have reported that they have no relationships to disclose.(by up to 80%) resulting in an increased fraction of active
(not acetylated) platelet COX and an increased proportion
of nonaspirinated platelets. Aspirin is administered once
daily, and most platelets produced during the 24-h dosing
interval remain uninhibited until the next dose, because
aspirin has a half-life of only 13 to 19 min (10). In addition,
Zimmermann et al. (11) reported that incomplete inhibition
of platelet COX-1 by aspirin after CABG surgery, as
measured by persistent thromboxane production and plate-
let aggregation in response to arachidonic acid, could not be
overcome in vitro by high concentrations of aspirin (100
mol/l) that exceeded those in plasma after oral aspirin
treatment. They suggested that aspirin resistance after
CABG seemed to result from an impaired interaction of
aspirin with platelet COX (11), but the actual mechanism(s)
responsible for reduced platelet-inhibitory effect of aspirin
after CABG surgery has been uncertain until now.
In this issue of the Journal, Mattiello et al. (12) present
preliminary data on a new, hitherto unrecognized mecha-
nism of aspirin resistance that could explain suboptimal
platelet inhibition by aspirin in patients who have under-
gone recent CABG surgery. Mattiello et al. (12) hypothe-
sized that CABG surgery leads to an upregulation of the
unidirectional transporter multidrug resistance protein-4
(MRP4) in the plasma membrane of platelets; the upregu-
lated MRP4 increases active transport of aspirin, an organic
ion, from the platelet cytosol to the outside of the cell; the
concentration of aspirin in the cytosol falls; and there is less
aspirin available to inhibit COX-1–dependent platelet ag-
gregation (Fig. 1). Furthermore, Mattiello et al. hypothe-
sized that pre-treatment with the MRP4 inhibitors, dipy-
ridamole and Mk-571, would inhibit MRP4-mediated
transport of aspirin out of the platelet and thereby promote
accumulation of aspirin in platelets and aspirin-mediated
inhibition of COX-1–dependent thromboxane production
and platelet aggregation.
To test this hypothesis Mattiello et al. (12) performed a
series of elegant experiments with platelet preparations
obtained from patients undergoing CABG surgery and
from healthy volunteers. In their first set of experiments,
they used 14C-labelled aspirin, fluorescent cyclic adenosine
onophosphate (a known MRP4 substrate), and various
RP4 inhibitors to establish that: 1) aspirin is a substrate
or MRP4; and 2) MRP4 inhibitors prevent platelet aspirin
nd salicylic acid (the metabolite of aspirin) transport into
ense granules and out of the platelet, increase intra-platelet
spirin and salicylic acid concentrations, and enhance the
OX-1–inhibitory effect of aspirin. Thromboxane is also a
ubstrate for the MRP4 efflux pump, but Mattiello et al.
12) showed that suppression of thromboxane concentra-
ions after the addition of an MRP4 inhibitor was due to
nhanced aspirin action (i.e., greater COX-1 inhibition)
ather than any important direct effect of MRP4 on throm-
oxane release.
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confirmed the role of MRP4 in aspirin transport with
platelets obtained from an in vitro cell culture system and
megakaryocytes transfected with a small interfering ribonu-
cleic acid that interferes with expression of MRP4. Com-
pared with platelets obtained from untransfected mega-
karyocytes, platelets obtained from MRP4 small interfering
ribonucleic acid-transfected megakaryocytes demonstrated
increased cytosolic concentrations of aspirin and salicylic
acid and reduced concentrations of thromboxane, findings
that are consistent with the role of MRP4 in aspirin
transport.
The third set of experiments involved the use of immu-
noblot, immunoelectron microscopy, and immunofluores-
cence studies to demonstrate that—compared with platelets
collected from healthy volunteers—platelets collected 5 and
10 days after procedure from patients undergoing CABG
surgery had increased MRP4 expression. The MRP4 ex-
pression was preferentially localized at the plasma mem-
brane on day 5 compared with day 10 after surgery.
Multidrug resistance proteins are adenosine triphosphate-
dependent efflux pumps localized in cellular plasma mem-
branes that have broad substrate specificity for transport of
endogenous anionic substances and play a key role in
hepatobiliary, renal, and intestinal drug elimination (13).
One of 9 distinct multidrug resistance proteins, MRP4 is
expressed in the membrane of platelet dense granules in
platelets and, to a lesser extent, in the plasma membrane of
platelets (14) as well as in red cells, the kidney, prostate, and
liver (15). Drug substrates for MRP4 include nucleoside
analogues used in the treatment of human immunodefi-
ciency virus as well as antibiotic and antineoplastic agents.
Inhibition of MRP4 by dipyridamole could explain the
enhanced thromboxane suppression that has previously been
reported when dipyridamole is added to aspirin (16). Genes
encoding MRPs are highly polymorphic (17), and variants
leading to lack of functional protein account for hereditary
aspirin
inhibition COX-1
TXA2
A
Figure 1 Possible Role of MRP4 in Transport of Aspirin Out of
Before coronary artery bypass graft (CABG) surgery, there is minimal multidrug res
gery, MRP4 is upregulated on the plasma membrane and promotes active transpo
and there is less aspirin available to inhibit cyclooxygenase (COX)-1–dependent pl
ridamole that inhibit MRP4-mediated transport. TXA2  thromboxane A2.conditions such as Dubin-Johnson syndrome (MRP2 defi- rciency) and pseudoxanthoma elasticum (MRP6 deficiency).
To date, however, no disease has been directly linked to
altered MRP4 activity.
Mattiello et al. (12) are the first to demonstrate that
aspirin is a substrate for MRP4, and their data provide a
plausible mechanism for post-CABG aspirin resistance and
the attendant increase in risk of cardiovascular events (18).
As with so many new discoveries, these findings raise
important new questions. What is the mechanism of up-
regulation of MRP4 after CABG surgery? Does MRP4
upregulation also occur in other high platelet production
states (e.g., acute coronary syndromes, bleeding, sepsis) and
contribute to the aspirin resistance that has been reported in
patients with acute coronary syndrome and undergoing
percutaneous coronary intervention and in patients with
diabetes? From a therapeutic perspective, the most impor-
tant question is whether MRP4-induced aspirin resistance
can be overcome by more frequent doses of aspirin or by the
use of an MRP4 inhibitor such as dipyridamole and, if so,
whether this leads to an improvement in clinical outcomes?
If the favorable effect of adding dipyridamole to aspirin in
patients with previous ischemic stroke of arterial origin is
mediated by inhibition of MRP4-mediated transport (19),
re there other, more potent inhibitors of MRP4-mediated
ransport—such as cilostazol (20)—that might further en-
ance the effectiveness of aspirin?
Further studies are clearly required to validate and extend
he provocative findings by Mattiello et al. (12) concerning
he role of MRP4 in post-CABG aspirin resistance. Mo-
ecular studies should ideally be performed in parallel with
unctional and biochemical studies to examine the potential
ole of MRP4 gene polymorphisms that alter the expression
nd function of the transporter as determinants of the
ccurrence and severity of aspirin resistance (17). Confir-
ation of the causal role of MRP4 in aspirin resistance
ould give rise to new more effective antiplatelet strategies
or patients undergoing CABG surgery, thereby potentially
irin
less
inhibition
COX-1
TXA2
MRP4
lets
e protein 4 (MRP4) expression on the plasma membrane (A). After CABG sur-
spirin out of the platelet (B). The concentration of aspirin in the cytosol falls,
aggregation. Transport of aspirin out of the cell is reduced by drugs such as dipy-asp
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Overexpression of MRP4 in CABG August 9, 2011:762–4cardiovascular events in these patients. If MRP4 is also
shown to contribute to aspirin resistance in other clinical
settings, the future of aspirin alone as the foundation
antiplatelet therapy in high-risk populations (21) could be
challenged by alternative treatments that are less vulnerable
to this mechanism. In the meantime, however, aspirin has
been proven to be effective for the prevention of graft failure
(22,23) and is likely also effective for the prevention of major
cardiovascular events in patients undergoing CABG surgery
(24) and thus should continue to be used according to
guideline recommendations (25,26).
Reprint requests and correspondence: Dr. John W. Eikelboom,
Population Health Research Institute, 237 Barton Street East,
Hamilton, Ontario L8L 2X2, Canada. E-mail: eikelbj@
mcmaster.ca.
REFERENCES
1. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose
aspirin for the prevention of atherothrombosis. N Engl J Med
2005;353:2373–83.
2. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006;367:
606 –17.
3. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman
MV. Association of laboratory-defined aspirin resistance with a higher
risk of recurrent cardiovascular events: a systematic review and meta-
analysis. Arch Intern Med 2007;167:1593–9.
4. Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens
BJ, Huisman MV. Prevalence of persistent platelet reactivity despite
use of aspirin: a systematic review. Am Heart J 2007;153:175–81.
5. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin
“resistance” and risk of cardiovascular morbidity: systematic review and
meta-analysis. BMJ 2008;336:195–8.
6. Patrono C, Rocca B. Drug insight: aspirin resistance—fact or fashion?
Nat Clin Pract Cardiovasc Med 2007;4:42–50.
7. Gorog DA, Sweeny JM, Fuster V. Antiplatelet drug ‘resistance.’ Part
2: laboratory resistance to antiplatelet drugs-fact or artifact? Nat Rev
Cardiol 2009;6:365–73.
8. Sweeny JM, Gorog DA, Fuster V. Antiplatelet drug ‘resistance.’ Part
1: mechanisms and clinical measurements. Nat Rev Cardiol 2009;6:
273–82.
9. Santilli F, Rocca B, De Cristofaro R, et al. Platelet cyclooxygenase
inhibition by low-dose aspirin is not reflected consistently by platelet
function assays: implications for aspirin “resistance.” J Am Coll
Cardiol 2009;53:667–77.
10. Zimmermann N, Kienzle P, Weber AA, et al. Aspirin resistance after
coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001;121:
982–4.
11. Zimmermann N, Wenk A, Kim U, et al. Functional and biochemical
evaluation of platelet aspirin resistance after coronary artery bypass
surgery. Circulation 2003;108:542–7.12. Mattiello T, Guerriero R, Vittoria Lotti L, et al. Aspirin extrusion
from human platelets through multidrug resistance protein-4 –
mediated transport: evidence of a reduced drug action in patients after
coronary artery bypass grafting. J Am Coll Cardiol 2011;58:752–61.
13. Keppler D. Multidrug resistance proteins (MRPs, ABCCs): impor-
tance for pathophysiology and drug therapy. Handb Exp Pharmacol
2011;201:299–323.
14. Jedlitschky G, Tirschmann K, Lubenow LE, et al. The nucleotide
transporter MRP4 (ABCC4) is highly expressed in human platelets
and present in dense granules, indicating a role in mediator storage.
Blood 2004;104:3603–10.
15. Russel FG, Koenderink JB, Masereeuw R. Multidrug resistance
protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and
signalling molecules. Trends Pharmacol Sci 2008;29:200–7.
16. Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ.
Effect of enteric coating on antiplatelet activity of low-dose aspirin in
healthy volunteers. Stroke 2006;37:2153–8.
17. Abla N, Chinn LW, Nakamura T, et al. The human multidrug
resistance protein 4 (MRP4, ABCC4): functional analysis of a highly
polymorphic gene. J Pharmacol Exp Ther 2008;325:859–68.
18. Gluckman TJ, McLean RC, Schulman SP, et al. Effects of aspirin
responsiveness and platelet reactivity on early vein graft thrombosis
after coronary artery bypass graft surgery. J Am Coll Cardiol 2011;57:
1069–77.
19. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A, ESPRIT
Study Group. Aspirin plus dipyridamole versus aspirin alone after
cerebral ischaemia of arterial origin (ESPRIT): randomised controlled
trial. Lancet 2006;367:1665–73.
20. Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention
of secondary stroke (CSPS 2): an aspirin-controlled, double-blind,
randomised non-inferiority trial. Lancet Neurol 2010;9:959–68.
21. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and
secondary prevention of vascular disease: collaborative meta-analysis of
individual participant data from randomised trials. Lancet 2009;373:
1849–60.
22. Goldman S, Copeland J, Moritz T, et al. Improvement in early
saphenous vein graft patency after coronary artery bypass surgery with
antiplatelet therapy: results of a Veterans Administration Cooperative
Study. Circulation 1988;77:1324–32.
23. Goldman S, Copeland J, Moritz T, et al. Saphenous vein graft patency
1 year after coronary artery bypass surgery and effects of antiplatelet
therapy. Results of a Veterans Administration Cooperative Study.
Circulation 1989;80:1190–7.
24. Filion KB, Pilote L, Rahme E, Eisenberg MJ. Perioperative use of
cardiac medical therapy among patients undergoing coronary artery
bypass graft surgery: a systematic review. Am Heart J 2007;154:
407–14.
25. Becker RC, Meade TW, Berger PB, et al. The primary and secondary
prevention of coronary artery disease: American College of Chest
Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Chest 2008;133:776S–814S.
26. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline
update for coronary artery bypass graft surgery: summary article. A
report of the American College of Cardiology/American Heart Asso-
ciation Task Force on Practice Guidelines (Committee to Update the
1999 Guidelines for Coronary Artery Bypass Graft Surgery). J Am
Coll Cardiol 2004;44:e213–310.Key Words: aspirin y bypass y MRP4 y platelets.
